Radioiodine Therapy for Thyroid Cancer in the Era of Risk Stratification and Alternative Targeted Therapies

Pryma, Daniel A.

doi:10.2967/jnumed.113.131508

Cited by 30 publications

(18 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with low-and intermediate-risk differentiated thyroid carcinoma (DTC) are selectively treated with postoperative radioactive iodine (I-131) ablation; however, the indication for I-131 therapy is the subject of an ongoing debate, and there is no consensus regarding optimal I-131 activity in this group of patients [1][2][3][4][5][6][7]. Following a single application of I-131, approximately 8-40% of patients require an additional application (re-ablation) due to ablation failure.…”

Section: Introductionmentioning

confidence: 99%

Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma

Prpić¹,

Kruljac

Kust³

et al. 2016

Endocrine

View full text Add to dashboard Cite

Results: Re-ablation was successful in 113 out of 128 patients (88.3%). Mean first I-131 activity was 2868 ± 914 MBq (77.5 ± 24.7 mCi), and mean second I-131 activity 3004 ± 699 MBq (81.2 ± 18.9 mCi). There was no association between the first, second, and cumulative activity with reablation treatment outcome. Treatment failure was associated with higher Tg levels prior to reablation (Tg2) (OR 1.16, 95% CI 1.05 -1.29, P=0.003) and N1a status (OR 3.89, P=0.032). After excluding patients with positive-to-negative TgAb conversion, Tg2 level of 3.7 ng/mL predicted treatment failure with a sensitivity of 75.0 %, specificity of 80.5%, and a negative predictive value of 97.1%. Patients with positive-to-negative TgAb conversion had higher failure rates (OR=2.96, 95% CI 0.94 -9.29).3 Conclusions: Re-ablation success was high in all subgroups of patients and I-131 activity did not influence treatment outcome. Tg may serve as a good predictor of re-ablation failure. Patients with positive-to-negative TgAb conversion represent a specific group, in whom Tg level should not be used as a predictive marker of treatment outcome.

show abstract

Section: Introductionmentioning

confidence: 99%

Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma

Prpić¹,

Kruljac

Kust³

et al. 2016

Endocrine

View full text Add to dashboard Cite

show abstract

“…One of them is the radioiodine therapy. It has been used for well-differentiated thyroid cancer [2].…”

mentioning

confidence: 99%

Uptake and Cytotoxicity Characterization of Radioiodine in MCF-7 and SKBR3 Breast Cancer Cell Lines

et al. 2016

View full text Add to dashboard Cite

Radioiodine is an effective and low-risk therapy modality in well-differentiated thyroid cancer patients post near-total thyroidectomy. Extra thyroidal tumors such as breast cancer are known to be able to uptake radioiodine. The aim of this study was to analyze the uptake, efflux and cytotoxicity of radioiodine for two molecular types of breast cancer cell lines. Two types of breast cancer cell lines were used in this study, MCF-7 (luminal A type) and SKBR3 (HER2 type). The HaCaT cell line was used as normal cells. Iodine-125 (I-125) was used to measured radioiodine uptake and efflux. Clonogenic assay was used to assess cytotoxicity of iodine-131 (I-131) based on the tested cell reproductive ability. The radioiodine uptake in SKBR3 cells was found to be higher than that of MCF-7 and HaCaT cells at p<0.05. The reproductive ability of MCF-7 cells are lower than SKBR3 cells at p<0.05. Both breast cancer cells have less reproduction ability than HaCaT cells at p<0.05. Both types of breast cancer cells present the ability to uptake radioiodine and show a high sensitivity to radioiodine exposure. Normal cells also demonstrate an ability to uptake radioiodine. However, they have a better tolerance to the amount of I-131 exposure. These findings could potentially lead to the use if I-131 for ablative therapy in breast cancer, similiar to its use in the treatment of thyroid cancer.

show abstract

“…Further RAI can be given to patients that have persistent biochemical evidence of disease, and although repeat RAI is often less effective than the initial RAI treatment (especially for patients with persistent structural disease), it can be effective at driving some patients with persistent biochemical disease into remission 37 . Thus, strategies designed to improve the tumoricidal effect of the initial RAI dose should result in higher remission and cure rates 30 .…”

Section: Medical Oncologist's Opinion: Oligo-metastatic Dtc Treated Wmentioning

confidence: 97%

Four Difficult Thyroid Cancer Cases: Incorporating Medical Therapies

McFarland

Dang

Miles

et al. 2015

Seminars in Oncology

View full text Add to dashboard Cite

Radioiodine Therapy for Thyroid Cancer in the Era of Risk Stratification and Alternative Targeted Therapies

Cited by 30 publications

References 43 publications

Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma

Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma

Uptake and Cytotoxicity Characterization of Radioiodine in MCF-7 and SKBR3 Breast Cancer Cell Lines

Four Difficult Thyroid Cancer Cases: Incorporating Medical Therapies

Contact Info

Product

Resources

About